COMPASS Pathways plc — FY2020 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2020; comparisons are with FY2019. This is an annual report, not a standalone fourth-quarter filing, and it does not provide clear Q4-only financial values. Financial statements are prepared under U.S. GAAP and presented in U.S. dollars unless stated otherwise.
Business context
COMPASS is a clinical-stage mental health company with no approved products or revenue. Its lead program is investigational COMP360 psilocybin therapy, administered with psychological support, initially for treatment-resistant depression (TRD). The company completed its U.S. IPO in September 2020.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $23.4 million | $12.6 million |
| General and administrative expense, including related-party fees | $28.0 million | $8.6 million |
| Total operating expenses / operating loss | $51.4 million | $21.2 million |
| Net loss | $60.3 million | $19.6 million |
| Net loss per share, basic and diluted | $3.55 | $2.62 |
| Net cash used in operating activities | $41.4 million | $17.8 million |
| Cash and cash equivalents at year-end | $190.3 million | $25.0 million |
| Working capital at year-end | $195.5 million | $8.3 million |
| Total assets / shareholders’ equity | $203.5 million / $196.6 million | $32.4 million / $(30.4) million |
Margins: Not meaningful because the company had no revenue. Debt: No convertible notes remained outstanding at year-end; the 2019 notes converted into preferred shares in April 2020, and preferred shares converted into ordinary shares at the IPO. Year-end operating lease commitments were $1.0 million, all due within one year. No dividends were paid.
Changes versus FY2019 and unusual items
- Net loss increased by $40.7 million, as operating expenses rose by $30.2 million and other income/expense worsened by $10.5 million.
- R&D expense increased $10.8 million, reflecting higher clinical and preclinical activity, hiring, and share-based compensation. G&A increased $19.4 million, including higher public-company, legal, personnel, and share-based compensation costs.
- Non-cash share-based compensation was $18.0 million, versus $3.3 million in 2019. The filing attributes significant charges to executive option vesting and acceleration associated with the IPO.
- Foreign exchange losses were $11.7 million, versus $0.1 million in 2019, largely related to U.S.-dollar cash held by an entity with pound-sterling functional currency. The company reported a $14.7 million foreign-currency translation gain in other comprehensive income.
- UK R&D tax-credit benefit was $4.2 million, versus $2.7 million. Financing provided $194.2 million of net cash, including $132.8 million of IPO proceeds and $61.3 million from Series B preferred shares.
- Cash flow from investing activities was $(0.6) million, including a $0.5 million investment for an 8% fully diluted stake in Delix Therapeutics.
Outlook, management commentary, risks and contingencies
- Management estimates year-end cash and cash equivalents can fund operating expenses and capital requirements through 2023. This estimate depends on assumptions and could prove inaccurate; the company expects substantial future losses and may need additional financing.
- The 216-patient Phase IIb TRD trial was ongoing across 22 sites in North America and Europe, testing 1 mg, 10 mg and 25 mg doses. Management targeted results in late 2021, subject to COVID-19 effects. The filing gives no formal revenue or earnings guidance.
- COVID-19 had interrupted enrollment and affected trial sites and supply-chain planning; enrollment resumed progressively during 2020, but further delays remained possible. A Phase II study evaluating COMP360 alongside SSRIs and a long-term follow-up study were also underway.
- Three suspected unexpected serious adverse reactions had been reported in the Phase IIb trial, including adjustment disorder and suicidal ideation; investigators considered them possibly related to study medication. The Data Safety Monitoring Board reviewed the first two cases and advised continuation without protocol amendments. A death reported in an investigator-initiated study occurred more than two months after COMP360 administration; the company considered it unlikely to be related, while noting it could not rule out a relationship.
- Key risks include clinical and regulatory failure or delay; psilocybin’s controlled-substance status and uncertain scheduling; safety and public-perception concerns; dependence on third-party manufacturers, clinical sites and therapists; reimbursement and commercialization uncertainty; competition; and funding needs. The company relied on a single API supplier, although it had identified possible backup suppliers.
- The company reported no material litigation or material contingency reserves at year-end. Its consolidated financial statements received an unqualified audit opinion. Management said previously identified material weaknesses in financial-reporting controls had been remediated by December 31, 2020; however, the filing did not include management’s annual internal-control assessment or an auditor attestation, citing applicable transition exemptions.
Important facts for investors to verify
- Whether the Phase IIb trial met its endpoints, how final safety results compare with the reported SUSARs, and whether the reported timeline or trial plans changed.
- Whether the cash-through-2023 estimate remains supportable given operating cash use, trial costs, and other spending.
- Whether the foreign-exchange exposure and the $11.7 million FY2020 exchange loss have been reduced or otherwise addressed.
- Progress on regulatory requirements and controlled-substance scheduling, manufacturing capacity and backup API supply, therapist/site readiness, and payer reimbursement planning.
- Whether internal controls remain effective and whether additional financing, equity dilution, or material contingencies have arisen since year-end.